Nucleic acid molecules encoding prostate specific antigen oligo epitope peptides
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsJeffrey Schlom, Kwong-yok Tsang, Sam Zaremba
Life of this patent
Estimating the term…
Abstract
The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.
Claims35
An isolated nucleic acid molecule which encodes a prostate specific antigen oligo-epitope peptide (PSA-OP) consisting of the amino acid sequence:
- (a)
- (SEQ ID NO:
- 4)
- F L T P K K L Q C V D L
- 141 142 143 144 145 146 147 148 149 150 151 152
- H V I S N D V C A Q V H
- 153 154 155 156 157 158 159 160 161 162 163 164
- P Q K V T K
- 165 166 167 168 169 170
- or
- (b) SEQ ID NO:
- 4 wherein valine is substituted for an amino acid residue at one or more positions selected from the group consisting of position 148, position 149, position 160 and position 161, or wherein at least one of the amino acids at positions 151, 152 and 153 is deleted.
An isolated nucleic acid molecule which encodes a prostate specific antigen oligo-epitope peptide (PSA-OP) consisting of the amino acid sequence of SEQ ID NO:
- 4.
An isolated nucleic acid molecule consisting of SEQ ID NO:
- 5 or SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.